GE HealthCare has launched a handheld, wireless ultrasound imaging system, dubbed Vscan Air SL, for rapid assessments of cardiac and vascular patients.

The medical technology company has designed Vscan Air SL for rapid assessments at the point of care to expedite the diagnosis and treatment decisions of clinicians.

The latest model in the Vscan product line, the Vscan Air SL, incorporates GE HealthCare’s proprietary SignalMax and XDclear technologies, which deliver high levels of penetration, resolution, and sensitivity in imaging performance.

The pocket-sized, portable ultrasound device is intended to allow clinicians to efficiently gather and view crystal-clear cardiac and vascular pictures at the point of care.

According to the company, physicians can speed up care decisions to assist patients in receiving treatment plans straight away by streamlining the workflows and avoiding overloaded traditional imaging resources.

The device also enables clear, whole-body scanning and secure viewing of images, GE HealthCare said.

Additionally, the ultrasound device has Vscan Air + Digital Tools that connect clinicians with a range of easy-to-use solutions.

Available through subscriptions, these tools are designed to enhance workflow with secure collaboration, image, and device management features.

GE HealthCare Point of Care and Handheld Ultrasound global general manager Dietmar Seifriedsberger said: “Vscan Air SL enables clinicians to make quick cardiac assessments and adds to our broad portfolio of ultrasound technologies to help further inform clinical decision-making at the point of care.

“This newest innovation demonstrates our commitment to providing integrated solutions resulting in a better standard of care delivery — and ultimately helping clinicians improve patient outcomes.”

In 2021, the medical technology company launched Vscan Air CL, its smallest and most lightweight handheld ultrasound device.

Currently, Vscan Air SL is commercially available in key nations across Europe, Asia, Australia, and New Zealand.

The device will be made commercially available in the US this quarter after receiving 510(k) clearance from the US Food and Drug Administration (FDA).